Aligos Therapeutics Inc. (ALGS) Live Share Price, Invest From India

Aligos Therapeutics Inc. Stock Performance

as on June 19, 2026 at 2:16 pm IST

Day's Low
Day's High
$5.18
Day's Price Range
$5.43
$5.28
1.89%
Downside
2.84%
Upside
52 Week's Low
52 Week's High
$4.80
52-Week Price Range
$13.69
$5.28
9.09%
Downside
159.27%
Upside

Aligos Therapeutics Inc. share price movements today

Previous Close: $5.35
Open: $5.25
Volume: 657.8K
Day's Low - High: $5.18 - $5.43
52 Week Low - High: $4.80 - $13.69

Aligos Therapeutics Inc. Historical Returns

1 Month Return: + 1.93 %
3 Month Return: -28.07 %
1 Year Return: -36.92 %
3 Year Return: -80.8 %
5 Year Return: -99.18 %

Aligos Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Aligos Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$33.1M

EPS (TTM)

-7.1133

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-94.6M

Revenue (TTM)

4.7M

Profit Margin

0.00%

Return On Equity TTM

-121.86%

Aligos Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aligos Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Aligos Therapeutics Inc.	BUY	$33.1M	-99.18%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$37.7B	57.21%	71.21	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$116.5B	140.42%	27.22	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$63.7B	13.39%	14.85	29.65%	0.58%

Stock Returns calculator for Aligos Therapeutics Inc. Stock including INR - Dollar returns

The Aligos Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Aligos Therapeutics Inc. investment value today

Current value as on today

₹68,715

Returns

-₹31,285

(-31.29%)

Returns from Aligos Therapeutics Inc. Stock

-₹36,918 (-36.92%)

Dollar Impact

₹5,632 (+5.63%)

Analyst Recommendation on Aligos Therapeutics Inc. Stock

Based on 8 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 8 analysts, 75% of analysts recommend a 'BUY' rating for Aligos Therapeutics Inc.. Average target price of $56.29

Aligos Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Aligos Therapeutics Inc..

What analysts predicted

90.62%UPSIDE

Target Price

$56.29

Current Price

$5.28

Analyzed by

8 Analysts

Target

$56.29

Aligos Therapeutics Inc. target price $56.29, a slight upside of 90.62% compared to current price of $5.28. According to 8 analysts rating.

Indian Investors' Interest in Aligos Therapeutics Inc. Stock

Search interest for Aligos Therapeutics Inc. Stock has increased by 79% in the last 30 days, reflecting an upward trend in search activity.

Time period: May 21, 2026 to June 20, 2026

Change:79% versus previous 30 day period

Aligos Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	2	0	1	1	0	0	0	0	0	2
Gross Profit	2	0	0	1	0	0	0	0	0	2
Operating Income	-25	-22	-26	-20	-20	-19	-18	-28	-21	-26
EBITDA	-27	-34	5	-18	-81	43	-15	-30	-19	-22
Interest Expense	1	12	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-27	-34	5	-19	-82	43	-15	-31	-19	-22
Income Tax Expense	0	0	0	0	0	0	0	0	0	0
Net Income	-27	-34	5	-19	-82	43	-15	-31	-19	-23
Net Profit Margin	-1040.36%	-3535.80%	477.00%	-1517.65%	-13060.41%	13854.66%	-1643.83%	-4256.01%	-11763.91%	-814.13%

Aligos Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-10	4	13	15	3	2
Gross Profit	-1	-2	-10	4	13	15	3	1
Operating Income	-13	-54	-97	-128	-97	-88	-89	-87
EBITDA	-12	-49	-94	-124	-93	-83	-128	-22
Interest Expense	-	1	10	0	1	-	-	-
Depreciation	1	2	3	3	3	3	2	2
Income Before Tax	-13	-52	-108	-128	-95	-86	-130	-23
Income Tax Expense	0	0	0	0	0	0	0	0
Net Income	-13	-52	-108	-128	-96	-87	-131	-24
Net Profit Margin	0.00%	0.00%	1029.04%	-2944.07%	-690.63%	-564.61%	-3326.01%	-1106.72%

Aligos Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-34	5	-19	-82	43	-15	-31	-19	-23
Operating Cash Flow	-22	-19	-20	-18	-20	-15	-24	-21	-23
Investing Cash Flow	-88	39	10	19	-44	-39	47	-2	34
Financing Cash Flow	0	0	0	0	101	0	0	0	0
Change in Cash	-111	20	-9	1	36	-55	23	-23	11

Aligos Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-52	-108	-128	-96	-87	-131	-24
Operating Cash Flow	-46	-74	-115	-79	-78	-80	-82
Investing Cash Flow	6	32	3	-26	44	-18	-37
Financing Cash Flow	85	192	78	0	88	0	101
Change in Cash	45	150	-33	-105	54	-98	-18

Global Institutional Holdings in Aligos Therapeutics Inc.

Funds	Holdings
XTX Topco Ltd	0.23%
Squarepoint Ops LLC	0.27%
Readystate Asset Management LP	3.29%
Deep Track Capital, LP	7.18%
UBS Group AG	0.6%

See all

Insights on Aligos Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 169.0K → 2.83M (in $), with an average increase of 94.0% per quarter
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.7% return, outperforming this stock by 49.8%
NO EFFECT
Against Peers
In the last 3 years, Aligos Therapeutics, Inc. Common Stock has experienced a drawdown of -79.7%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 57.8%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -19.88M → -23.04M (in $), with an average decrease of 15.9% per quarter
NEGATIVE IMPACT
Price Dip
In the last 6 months, ALGS stock has moved down by -50.6%

About Aligos Therapeutics Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Organisation	Aligos Therapeutics Inc.
Headquarters	One Corporate Drive, South San Francisco, CA, United States, 94080
Industry	Biotechnology
CEO	Dr. Lawrence M. Blatt MBA, Ph.D.
E-voting on shares	Click here to vote

Key Management of Aligos Therapeutics Inc.

Name	Title
Dr. Sushmita M. Chanda DABT, Ph.D.	Executive Vice President & Chief Development Officer
Dr. Tse-I Lin Ph.D.	Senior VP of Early Compound Development & Belgian Site Head
Dr. Kieron Wesson Ph.D.	Vice President & Head of Chemistry Manufacturing Controls
Dr. Lawrence M. Blatt MBA, Ph.D.	CEO, President & Chairman of the Board
Mr. Nikhil Aneja	Principal Accounting Officer
Ms. Laura Kavanaugh	VP & Head of Legal
Ms. Kristina Engeseth M.B.A.	Senior VP and Head of People & Culture
Dr. David B. Smith Ph.D.	Executive VP & Head of Chemical Operations
Dr. Ramon Polo M.B.A., Ph.D., Pharm.D.	Senior VP & Head of Global Regulatory Affairs
Dr. Julian A. Symons DPHIL	Executive VP & Chief Scientific Officer

FAQs

What is Aligos Therapeutics Inc. share price today?

Aligos Therapeutics Inc. share price today is $5.28 as on June 19, 2026 at 8:46 am IST at the close of the market. Aligos Therapeutics Inc. share today touched a day high of $5.43 and a low of $5.18.

What is the 52 week high and 52 week low for Aligos Therapeutics Inc. share?

Aligos Therapeutics Inc. share touched a 52 week high of $13.69 on December 15, 2025 and a 52 week low of $4.8 on June 5, 2026. Aligos Therapeutics Inc. stock price today i.e. June 19, 2026 at 8:46 am IST is closed at $5.28,which is 61.43% down from its 52 week high and 10.00% up from its 52 week low.

What is Aligos Therapeutics Inc.'s market capitalisation today?

Aligos Therapeutics Inc. market capitalisation is $0.00T as on June 19, 2026 at 8:46 am IST.

How to invest in Aligos Therapeutics Inc. Stock (ALGS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Aligos Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aligos Therapeutics Inc. Shares that will get you 0.2841 shares as per Aligos Therapeutics Inc. share price of $5.28 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Aligos Therapeutics Inc. Stock (ALGS) from India?

Indian investors can start investing in Aligos Therapeutics Inc. (ALGS) shares with as little as ₹94.31 or $1 (as of June 20, 2026 at 8:56 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Aligos Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on June 20, 2026 at 8:56 pm IST). Based on Aligos Therapeutics Inc. share’s latest price of $5.28 as on June 19, 2026 at 8:46 am IST, you will get 1.8939 shares of Aligos Therapeutics Inc.. Learn more about fractional shares .

What are the returns that Aligos Therapeutics Inc. has given to Indian investors in the last 5 years?

Aligos Therapeutics Inc. stock has given -99.18% share price returns and 27.5% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?